Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

Abstract:
Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat lung cancer. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants from NIH and the State of Maryland.

Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

Gaithersburg, MD | Posted on July 22nd, 2009

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and Takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development. There are more than a dozen clinical trials currently ongoing for various types of therapeutic applications.

Sirnaomics' mission is to advance RNAi technology by using its proprietary multi-targeted siRNA cocktail design together with the company's nanoparticle-mediated siRNA delivery vehicles in the rapid delivery of novel therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various diseases including H1N1/H5N1 influenza A infection, scarless wound healing and several types of cancers.

"Receiving an SBIR grant again from NCI clearly demonstrates the scientific and business merits of our lung cancer therapeutic program using multi-targeted siRNA cocktails," said Dr. Patrick Y. Lu, the founder, President and CEO of the company, also the Principal Investigator of the grant proposal. "It is a successful extension of Sirnaomics product pipeline for siRNA therapeutics." Dr. Lu further emphasized that the grants from various Government agencies provided a sustainable funding resource to the company in addition to its corporate partnership deals and venture capital investments. "Funding from Government is uniquely important for an early stage company like Sirnaomics, especially in the current financial environment."

####

About Sirnaomics, Inc.
Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has a mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. Members of the senior management team bring over 50 years of combined experience in the biopharmaceutical, financial and business management industries in both the US and China and the company has established a subsidiary in Suzhou, China to expand both its R&D capacity and potential market.

For more information, please click here

Contacts:
George J. Ji
Sirnaomics, Inc.
401 Professional Drive, Suite 130
Gaithersburg, MD 20879, USA
301-740-1730 Phone
301-740-1731 FAX

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Govt.-Legislation/Regulation/Funding/Policy

NNCO Announces an Interactive Webinar: Progress Review on the Coordinated Implementation of the National Nanotechnology Initiative 2011 Environmental, Health, and Safety Research Strategy July 23rd, 2014

Nano-sized Chip "Sniffs Out" Explosives Far Better than Trained Dogs: TAU researcher's groundbreaking sensor detects miniscule concentrations of hazardous materials in the air July 23rd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

Penn Study: Understanding Graphene’s Electrical Properties on an Atomic Level July 22nd, 2014

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Announcements

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

EPFL Research on the use of AFM based nanoscale IR spectroscopy for the study of single amyloid molecules wins poster competition at Swiss Physics Society meeting July 22nd, 2014

Carbyne morphs when stretched: Rice University calculations show carbon-atom chain would go metal to semiconductor July 21st, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE